Transcend Therapeutics develops novel, rapid-acting treatments targeting neuropsychiatric diseases for patients underserved by current medications. The company's pipeline focuses on compounds like TSND-201, a neuroplastogen being investigated for severe Post-Traumatic Stress Disorder (PTSD). They aim to deliver robust and long-lasting therapeutic options through advanced pharmacological approaches.
Funding
$41.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current psychiatric medications are ineffective for a significant portion of patients suffering from neuropsychiatric disorders. This unmet need leaves many individuals without adequate relief from conditions like PTSD, major depressive disorder (MDD), and other central nervous system (CNS) disorders, impacting their functional outcomes and overall quality of life.
Solution
Transcend Therapeutics is developing TSND-201, a rapid-acting neuroplastogen, to address the limitations of existing treatments for neuropsychiatric diseases. TSND-201 enhances neuroplasticity by rapidly inducing the expression of neuroplasticity genes, such as BDNF, in brain areas associated with the pathophysiology of PTSD, depression, and other CNS disorders. Unlike classical psychedelics, TSND-201 is non-hallucinogenic and does not directly interact with 5-HT2A receptors. The company's approach aims to provide rapid, robust, and long-lasting improvements in neuroplasticity and behavior, translating to fast-acting and durable clinical benefits for patients.
Target Audience
The primary target audience includes individuals suffering from PTSD, major depressive disorder (MDD), and other central nervous system (CNS) disorders who have not responded adequately to existing psychiatric medications.
Features
- TSND-201 is a triple reuptake inhibitor and releaser (serotonin, norepinephrine, dopamine).
- Induces rapid and robust serotonin and norepinephrine release in the frontal cortex.
- Demonstrates rapid induction of neuroplasticity gene expression (e.g., BDNF) in relevant brain areas.
- Well-characterized primary pharmacology with no expected off-target toxicity based on GCPR analysis.
- Currently in Phase 2 clinical trials for PTSD, with ongoing research into MDD and other CNS disorders.
- Supported by a collaborative grant from the US DoD to further investigate its neuroplasticity mechanism of action.